Indeed, we found that, as in other studies21, DTCs express nuclear NR2F1, a well-established marker for dormancy used in different pre-clinical models20,21,43,44 as well as in the clinic for breast and prostate cancer patients42. The gene discussed is NR2F1; the disease is prostate carcinoma.